Show simple item record

dc.contributor.authorWarde, P
dc.contributor.authorHuddart, R
dc.contributor.authorBolton, D
dc.contributor.authorHeidenreich, A
dc.contributor.authorGilligan, T
dc.contributor.authorFossa, S
dc.date.accessioned2018-07-25T09:55:59Z
dc.date.issued2011-10
dc.identifier.citationUrology, 2011, 78 (4 Suppl), pp. S435 - S443
dc.identifier.issn0090-4295
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2127
dc.identifier.eissn1527-9995
dc.identifier.doi10.1016/j.urology.2011.02.031
dc.description.abstractThe treatment of patients with Stage I-II seminoma has changed considerably in the past decade, and in November 2009, an International Consensus meeting was held under the sponsorship of the Union for International Cancer Control (UICC), Société Internationale d'Urologie (SIU), and International Consultation on Urological Diseases (ICUD) to review recent updates in the published data and develop international consensus guidelines on the treatment of this group of patients. In Stage I disease, the consensus conference recommended that patients should be informed of all treatment options, including the potential benefits and side effects of each treatment. It was agreed that this discussion should include a review of the possible salvage treatment effects. In addition, in patients willing and able to adhere to a surveillance program, this should be considered the management option of choice (assuming facilities are available for suitable monitoring). For Stage IIA disease, the consensus conference recommended that radiotherapy should be considered the standard treatment in the absence of contraindications. For Stage IIB disease, chemotherapy or radiotherapy were considered reasonable treatment approaches, and for Stage IIC disease, chemotherapy should be considered the standard treatment approach. For patients with a residual mass after chemotherapy, the consensus conference noted that patients with masses <3 cm in diameter could likely be safely observed, and patients with residual masses >3 cm in diameter could be considered for immediate surgery or close observation. It was also noted that surgery in this setting is technically challenging and could be associated with greater morbidity than in patients with nonseminomatous tumors.
dc.formatPrint
dc.format.extentS435 - S443
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectSeminoma
dc.subjectTesticular Neoplasms
dc.subjectNeoplasm Staging
dc.subjectCombined Modality Therapy
dc.subjectChina
dc.subjectMale
dc.subjectPractice Guidelines as Topic
dc.titleManagement of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
dc.typeJournal Article
dcterms.dateAccepted2011-02-14
rioxxterms.versionofrecord10.1016/j.urology.2011.02.031
rioxxterms.licenseref.startdate2011-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfUrology
pubs.issue4 Suppl
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume78
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record